Stay updated with breaking news from Markus Heckmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 – ...
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule pro...
KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the...
NEW NOW Festival for Digital Arts 2023 opens in Essen, Germany.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today